Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.70 USD
+0.14 (25.35%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-0.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MTNB 0.70 +0.14(25.35%)
Will MTNB be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for MTNB based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MTNB
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners
Matinas BioPharma just downgraded at Alliance Global Partners, here's why
12 Health Care Stocks Moving In Thursday's Intraday Session